Deutsche Bank’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $164K | Sell |
42,389
-5,014
| -11% | -$19.4K | ﹤0.01% | 3183 |
|
|
2026
Q2 | $220K | Buy |
+47,403
| New | +$123K | ﹤0.01% | 3201 |
|
|
2021
Q2 | – | Sell |
-25,416
| Closed | -$55K | – | 4674 |
|
|
2021
Q1 | $55K | Sell |
25,416
-2,262
| -8% | -$5.07K | ﹤0.01% | 4210 |
|
|
2020
Q4 | $62K | Buy |
27,678
+7,474
| +37% | +$19.6K | ﹤0.01% | 4060 |
|
|
2020
Q3 | $54K | Buy |
20,204
+1,796
| +10% | +$5.03K | ﹤0.01% | 3852 |
|
|
2020
Q2 | $56K | Buy |
18,408
+4,582
| +33% | +$11.5K | ﹤0.01% | 3759 |
|
|
2020
Q1 | $28K | Sell |
13,826
-7,464
| -35% | -$18.2K | ﹤0.01% | 3801 |
|
|
2019
Q4 | $60K | Buy |
21,290
+9,406
| +79% | +$32.7K | ﹤0.01% | 3881 |
|
|
2019
Q3 | $42K | Sell |
11,884
-18,290
| -61% | -$66.1K | ﹤0.01% | 4023 |
|
|
2019
Q2 | $124K | Sell |
30,174
-30,580
| -50% | -$132K | ﹤0.01% | 4094 |
|
|
2019
Q1 | $309K | Buy |
+60,754
| New | +$292K | ﹤0.01% | 3739 |
|
|
2018
Q3 | – | Sell |
-1,300
| Closed | -$8K | – | 5418 |
|
|
2018
Q2 | $8K | Sell |
1,300
-1,300
| -50% | -$6.33K | ﹤0.01% | 5187 |
|
|
2018
Q1 | $12K | Buy |
2,600
+2,598
| +129,900% | +$12.1K | ﹤0.01% | 5092 |
|
|
2017
Q4 | $0 | Hold |
2
| – | – | ﹤0.01% | 5034 |
|
|
2017
Q3 | $0 | Sell |
2
-100
| -98% | -$198 | ﹤0.01% | 4947 |
|
|
2017
Q2 | $0 | Buy |
102
+100
| +5,000% | +$266 | ﹤0.01% | 4997 |
|
|
2017
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 4971 |
|
|
2016
Q4 | $0 | Hold |
2
| – | – | ﹤0.01% | 4962 |
|
|
2016
Q3 | $0 | Sell |
2
-11
| -85% | -$20 | ﹤0.01% | 5014 |
|
|
2016
Q2 | $0 | Sell |
13
-1,498
| -99% | -$2.2K | ﹤0.01% | 5232 |
|
|
2016
Q1 | $2K | Sell |
1,511
-3,975
| -72% | -$5.34K | ﹤0.01% | 5045 |
|
|
2015
Q4 | $8K | Buy |
5,486
+3,986
| +266% | +$9.13K | ﹤0.01% | 4970 |
|
|
2015
Q3 | $3K | Sell |
1,500
-1,958
| -57% | -$4.62K | ﹤0.01% | 5083 |
|
|
2015
Q2 | $9K | Buy |
3,458
+867
| +33% | +$2.61K | ﹤0.01% | 5064 |
|
|
2015
Q1 | $8K | Sell |
2,591
-28,919
| -92% | -$103K | ﹤0.01% | 4826 |
|
|
2014
Q4 | $109K | Sell |
31,510
-163
| -0.5% | -$720 | ﹤0.01% | 4674 |
|
|
2014
Q3 | $158K | Buy |
31,673
+86
| +0.3% | +$670 | ﹤0.01% | 4221 |
|
|
2014
Q2 | $435K | Buy |
31,587
+28,441
| +904% | +$354K | ﹤0.01% | 3573 |
|
|
2014
Q1 | $48K | Buy |
+3,146
| New | +$44.8K | ﹤0.01% | 4566 |
|
Other funds holding GALT
Deutsche Bank's GALT Position: Q3 2026 in Review
Deutsche Bank reduced its Galectin Therapeutics (GALT) stake by 11% in Q3 2026, selling an estimated $19.4K and leaving 42,389 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #3183.
Deutsche Bank first reported a position in GALT in Q1 2014 and has held it in 29 quarters since. The position peaked at $435K in Q2 2014. 83 funds tracked by Wall St. Rank hold GALT as of Q3 2026.
- Deutsche Bank held 42,389 shares of Galectin Therapeutics worth $164K as of Q3 2026.
- Deutsche Bank sold 5,014 Galectin Therapeutics shares in Q3 2026, an estimated $19.4K.
- Galectin Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #3183 holding.
- Deutsche Bank first reported a position in Galectin Therapeutics in Q1 2014 and has held it in 29 quarters since.
- Deutsche Bank's Galectin Therapeutics position peaked at $435K in Q2 2014.
- 83 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2026.
Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.